ROCKVILLE, Md.--(BUSINESS WIRE)--Oct. 9, 2012--
Emergent
BioSolutions Inc. announced today that it will report
financial results for the third quarter 2012 on Thursday, November 1,
2012, before market open.
Company management will host a conference call at 8:00 AM Eastern on
November 1, 2012 to discuss the financial results for the third quarter
and first nine months of 2012, recent business developments, revenue
guidance for the fourth quarter of 2012 and revenue and net income
guidance for full year 2012. The conference call will be accessible by
dialing 888/679-8037 or 617/213-4849 (international) and
providing passcode 34805828. A webcast of the conference call
will be accessible from the company’s website at www.emergentbiosolutions.com,
under “Investors”.
Emergent BioSolutions is offering call participants a pre-registration
option that expedites access to the call and minimizes hold times.
Pre-registrants will be issued a pin number to be used when dialing into
the live call which will provide quick access to the conference call by
bypassing the operator upon connection. Pre-registration, while not
mandatory, can be accessed using the following website: https://www.theconferencingservice.com/prereg/key.process?key=PP8VBC7JJ
A replay of the conference call will be accessible, approximately two
hours following the conclusion of the call, by dialing 888/286-8010 or
617/801-6888 and using the passcode 51609046. The replay will be
available through November 8, 2012. The webcast will be archived on the
company’s website, www.emergentbiosolutions.com,
under “Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions protects and enhances life by developing and
manufacturing vaccines and therapeutics that are supplied to healthcare
providers and purchasers for use in preventing and treating disease.
Emergent's marketed and investigational products target infectious
diseases, oncology and autoimmune disorders. Additional information
about the company may be found at www.emergentbiosolutions.com.
Follow us on Twitter: @emergentbiosolu
Source: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Investors Contact:
Robert G.
Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media
Contact:
Tracey Schmitt
Vice President, Corporate
Communications
301-795-1800
SchmittT@ebsi.com
